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 2 
Abstract 30 
We report on a molecular investigation carried out to ascertain the prevalence of drug resistant 31 
TB and the specific gene mutations responsible for resistance to rifampicin (RIF) and/or isoniazid 32 
(INH) in Iraq. One hundred and ten clinical isolates from category II TB cases from Baghdad 33 
(58%) and several Iraqi provinces (42%) were analyzed using colorimetric, low-cost and density 34 
(LCD) microarrays (MYCODirect and MYCOResist LCD-array kits, Chipron GmbH, Germany) to 35 
identify the point mutations responsible for resistance in Mycobacterium tuberculosis isolates. 36 
Seventy-six patients (69.1%) had resistant strains, of which 40 (36%) were MDRTB. Where 37 
mono-resistance was identified, it was found to be predominantly to RIF (83%). The most 38 
common mutations were rpoB S531L (50%), inhA C15T (25%), and katG S315T (15%). The 39 
most common MDRTB genotypes were rpoB S531L with inhA C15T (60%) and rpoB S531L 40 
with katG S315T (20%). Where phenotypic analysis of clinical isolates was also performed, 41 
genotypic data were found to show excellent correlation with phenotypic results. Correlation was 42 
found between the MYCOResist LCD-array and GenoType MTBDRplus for detection of resistance 43 
to RIF. Our study shows MDRTB in 36% of category II TB cases in Baghdad and surrounding 44 
Iraqi provinces which reflects World Health Organization (WHO) findings based on phenotypic 45 
studies. Diagnosis of TB and MDR-TB using culture-based tests are a significant impediment to 46 
global TB control. The LCD arrays investigated herein are easy to use, sensitive and specific 47 
molecular tools for TB resistance profiling in resource-limited laboratory settings. 48 
  49 
 3 
Introduction 50 
Tuberculosis (TB) is a major cause of mortality resulting in 2 million deaths globally and 9 million 51 
new cases annually (Brudey et al., 2006). According to the Iraq Ministry for Health, Iraq is ranked 52 
44th globally for TB incidence but 11th for TB mortality. Iraqi TB cases constitute 3% of total 53 
cases in the Eastern Mediterranean Region (World Health Organization (WHO), 2012b). Despite 54 
widespread application of the WHO's Directly Observed Treatment Strategy (DOTS) for TB 55 
control, TB incidence in Iraq has increased since 2003 to 117 per 100,000 population in 2010 56 
(World Health Organization (WHO), 2012a; Yousif et al., 2009). The country has been affected 57 
by conflict which has made it difficult to assess the extent of the problem. While TB incidence is 58 
high, case detection rates remain low; estimated at 43% in 2007 and 49% in 2010 (World Health 59 
Organization (WHO), 2012b). The National Tuberculosis Programme in Iraq aims to reach and 60 
maintain detection of 70% of infectious TB cases and cure at least 85% of those cases by 2013 61 
and also to reduce the prevalence of and deaths due to TB by 50% by 2015 (Iraq Ministry for 62 
Health, 2012). 63 
 64 
Multidrug-resistant tuberculosis (MDRTB), defined as tuberculosis showing resistance to at least 65 
isoniazid (INH) and Rifampicin (RIF), is diagnosed in >400,000 people annually (Frieden et al., 66 
1993; World Health Organization (WHO), 2007; Yew & Chau, 1995) and is a major public health 67 
problem in Iraq. Previous anti-tuberculosis therapy is the most significant predisposing factor for 68 
developing MDRTB (Sharma et al., 2011). The WHO reported a worldwide MDR-TB rate of 69 
4.3% of all TB cases in 2004 from which 29.4% were previously treated cases (Zignol et al., 70 
2006). During 2010, 3.4% of new cases and 21% of previously treated TB cases were confirmed 71 
as MDR-TB. The latest WHO global tuberculosis report 2014 described a worldwide MDR-TB 72 
rate of 3.5% in 2013 and a MDR-TB rate of 3.7% of new cases and 20% of retreatment cases in 73 
Iraq in the same year (World Health Organization (WHO), 2014); (www.who.int/tb/data; date 74 
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accessed: 15.10.2015). Ninety six percent of RIF-resistant M. tuberculosis occurs due to 75 
mutations in the 81bp RIF-resistance-determining region which encodes the -subunit of RNA 76 
polymerase. The molecular mechanisms of INH resistance are more complex with over 18 genes 77 
implicated. The catalase-peroxidase gene (katG) is mutated in 60-70% of cases.  In addition, 78 
mutations in inhA (which encodes a reductase used in mycolic acid biosynthesis) is associated 79 
with resistance to INH (Aragon et al., 2006; Rattan et al., 1998). The prevalence and type of 80 
mutations conferring resistance vary depending on geographical location (Sajduda et al., 2004; 81 
Sharma et al., 2003). 82 
 83 
Since 2006 XDRTB, defined as TB resistant to one of the fluoroquinolone drugs and to at least 84 
one of the three injectable second line drugs, has been deemed by WHO to pose a serious global 85 
threat to public health, particularly in countries with a high prevalence of HIV.  86 
Detection of mutations that confer resistance using genotypic methods is faster and lower risk 87 
than phenotypic drug susceptibility testing (DST) which requires growth of M. tuberculosis that 88 
can take up to several weeks (Soini & Musser, 2001). Commercial (Cinngen, Iran)  and in-house 89 
end point PCR methods have been used in Iraq to detect TB, however molecular studies and 90 
evaluation of resistance patterns are rare to date (Abbas & Al-Hamdani, 2009). One study carried 91 
out in Dohuk, Iraq gave insight into the molecular epidemiology of MDRTB using spoligotyping 92 
to genotype resistant M. tuberculosis strains (Merza et al., 2010). In this study with a limited 93 
number of 53 Iraqi patients with pulmonary TB Merza et al. identified MDR-TB in 7.9% of 94 
previously untreated patients and in 46.7% of previously treated patients. Knowledge of resistance 95 
patterns and trends is essential so that appropriate anti-TB treatment can be administered. 96 
 97 
LCD-arrays offer an easy way to detect resistance as minimal lab instrumentation is needed. Each 98 
chip contains eight identical microarrays separated in small reaction chambers. The labelled 99 
 5 
amplicons are hybridised to genus-specific or species-specific capture probes of 16-22 nt 100 
immobilised on the LCD-Chip surface in duplicate spots.  101 
 102 
The MYCODirect LCD-array includes two primer pairs with 3 genus-specific capture probes, two 103 
MTBC-specific capture probes and 13 capture probes for mycobacteria other than M. tuberculosis 104 
(MOTT). PCR products of 226 bp result from amplification of the genus-specific internal 105 
transcribed spacer (ITS). An additional fragment of 125–165 bp from the MTBC-specific 106 
insertion element IS6110 is also amplified depending on the species present. Due to the high 107 
degree of IS6110 sequence similarity between M. tuberculosis and M. bovis, the MYCODirect 108 
LCD-array does not allow discrimination between these species. The MYCOResist LCD-array will 109 
detect point mutations associated with drug resistance in M. tuberculosis. Triplex PCR results in 110 
simultaneous amplification of rpoB, inhA and katG genes to produce amplicons of 158 bp, 210 111 
bp and 248 bp respectively. The capture probes for rpoB span a 90 bp region coding for amino 112 
acids 504–534, with 6 probes representing the wild type sequence and 12 probes representing 113 
resistance-associated SNPs. katG probes interrogate codon 315 as the wt sequence and two SNPs 114 
associated with INH resistance. inhA probes represent three point mutations associated with 115 
resistance at nucleotides 8, 15 and 17 in addition to two probes which bind to the wild type 5’ 116 
non-coding region (3). The post-PCR protocol takes 45 min and results are read using a 117 
transmission-light scanner and analysed using automated software or online (www.chipron.com). 118 
 119 
 120 
Materials and Methods 121 
Specimen Collection 122 
Sputum specimens were obtained from 141 Category II pulmonary TB cases over a thirteen month 123 
period (September 2008 to October 2009). All patients had failed previous TB treatment, relapsed 124 
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after treatment or defaulted during previous treatment. Definition as Category II TB was based on 125 
patient medical history including symptoms, x- ray examination, post-treatment follow-up and 126 
demographic risk factors for TB. All patients were referred to the National reference laboratories 127 
or Centre of Tuberculosis & Chest Disease in Baghdad from hospitals, health centres, and 128 
consultant clinics.  129 
 130 
DNA from twelve MTBC isolates was received from the Scottish Mycobacteria Reference 131 
Laboratory (SMRL), Royal Infirmary of Edinburgh. Eight of these had phenotypic sensitivity 132 
results for INH and RIF. Sensitivity testing was performed using the absolute concentration 133 
method on LJ medium containing 40mg/L RIF and 0.2 mg/L INH according to WHO 134 
recommendations. Genotypic resistance to RIF and/or INH was detected by using GenoType 135 
MTBDRplus (HAIN Lifescience, Nehren, Germany) according to the manufacturer’s 136 
instructions. 137 
 138 
Phenotypic Characterisation 139 
Phenotypic DST for INH and RIF were performed at the Tuberculosis and Chest Diseases Unit 140 
(Preventive Medicine and Environmental Directorate, Ministry of Health, Iraq). Direct 141 
microscopy for acid-fast bacilli (AFB) using both Ziehl–Neelsen and Auramine Phenol was 142 
performed on 110 specimens after sputum pooling and decontamination with 2% sodium 143 
hydroxide and concentration. The sensitivity of ZN stain for AFB detection is regarded to be 104 144 
cfu/ml. In order to improve the sensitivity fluorescence microscopy was also applied. Three 145 
sputum specimens were used for evaluation of each patient as recommended by National 146 
guidelines of tuberculosis control (Mase et al., 2007) although recent recommendations from the 147 
World Health Organization now indicate that two specimens from the patient is sufficient for 148 
diagnosis (Noeske et al., 2009). Specimens were inoculated on Lowenstein–Jensen medium (LJ) 149 
prepared to the manufacturers instruction and incubated at 37°C 5-10% CO2 for 6 weeks.  150 
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Minimum inhibitory concentration (MIC) testing was performed on 22 samples for comparison 151 
with genotypic DST results. MIC testing allowed confirmation of antibiotic resistance and 152 
establishment of the lowest antibiotic concentration that inhibited the visible growth of the 153 
microorganism after incubation. Colonies were harvested from the culture and put in a sterile tube 154 
with equal amount of sterile distilled water and mixed well, and 10-2 and 10-4 of the bacterial 155 
suspension were cultivated on LJ slants and incubated at 37ºCfor up to 2 months. Cultures were 156 
checked daily for one week, followed by once weekly for 8 weeks.  157 
 158 
Genotypic Characterisation 159 
DNA Extraction 160 
DNA was extracted from each of the LJ slope culture using a freeze–thaw technique as described 161 
previously and purified using Wizard genomic DNA purification kit (Promega, Southampton, 162 
UK) (Reischl et al., 1994). Genomic DNA was visualised by agarose gel electrophoresis (GelDoc 163 
1000, Biorad, PeqPower E300, PeqLab, UK, GNA100, Amersham Bioscience). Following 164 
extraction, DNA was transported from Baghdad to UK at room temperature. DNA quantity and 165 
quality were then measured using a spectrophotometer (Nanodrop, Wilmington, DE, USA). 166 
 167 
PCR 168 
Multiplex PCR was performed using the labelled primers provided in the MYCODirect 1.7 and 169 
MYCOResist 3.5 LCD array kits (Chipron GmbH, Berlin, Germany) and HotStarTaq DNA 170 
Polymerase as per the manufacturer’s instructions. PCR products were visualised by agarose gel 171 
electrophoresis and capillary gel electrophoresis using a Bioanalyzer 2100 (Agilent Technologies, 172 
Wokingham, UK) for enhanced sensitivity in cases where product could not be visualised on a 173 
standard gel.  174 
 175 
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Chipron LCD Arrays 176 
MYCODirect hybridization is suited to testing of sputum samples without the need for culture 177 
providing a rapid identification of mycobacteria. In this study, culture was performed and as a 178 
result a small number of samples were tested using the species detection array. MYCOResist testing 179 
was performed on all 110 samples. Hybridization using MYCODirect and MYCOResistLCD-arrays 180 
was carried out as per the manufacturer’s instructions. Briefly, biotinylated PCR product was 181 
mixed with formamide-based hybridization buffer and 30µl applied to each LCD array on the chip 182 
(Aragon, Navarro, Heiser, Garrigo, Espanol & Coll, 2006). The chip was placed on a foam pad 183 
inside a humidity chamber (containing 250 µl water). The closed chamber was transferred to a 184 
36°C water bath for 30 min hybridisation. LCD-array chips were washed for 2 min in a low 185 
stringency buffer, placed in a Chipron transport container and dried using a centrifugation tool 186 
provided. The chips were incubated with 30µl streptavidin–horseradish peroxidase conjugate for 187 
5 min at room temperature followed by additional wash steps (Aragon, Navarro, Heiser, Garrigo, 188 
Espanol & Coll, 2006). The container was centrifuged at 1000 rpm for 1 min to dry the chip. After 189 
drying, 30µl substrate was added to each array for a 2 min creating a dark insoluble precipitate 190 
where hybridization has taken place. High-resolution greyscale images taken using a 191 
transmission-light film scanning device were analyzed using software provided.  192 
 193 
Hain GenoType MTBDRplus 194 
GenoType MTBDRplus (Hain Lifescience, Nehren, Germany) simultaneously identifies MTBC 195 
and resistance to RIF and/or INH from cultured isolates or smear-positive pulmonary specimens. 196 
PCR products are hybridised to a nitrocellulose strip containing 27 reaction zones including 11 197 
rpoB, katG and inhA wild type probes and 10 mutation probes to detect some of the most 198 
common mutations that confer resistance. The mutation probes for rpoB are designed to detect 199 
D516V (rpoB MUT1), H526Y (rpoB MUT2A), H526D (rpoB MUT2B) and S531L (rpoB 200 
MUT3). Two capture probes for the katG gene harbour the sequence for the mutations S315T1 201 
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(katG MUT1) and S315T2 (katG MUT2). The capture probes for inhA promoter region have 202 
been designed for four point mutations C15T, A16G, T8C, T8A. Following the manufacturer’s 203 
instructions, GenoType MTBDRplus was performed on eight DNA samples at SMRL and the 204 
results made available for this study. 205 
 206 
  207 
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Results 208 
Iraq TB study panel 209 
The geographical distribution of 110 patients included in the study is depicted in Figure 1A. 210 
Eighty-two patients (75%) were from Baghdad or the bordering provinces. Patient’s age ranged 211 
from 11-70 years but more than half of the TB cases (56%) were in the 20-40 age category (Figure 212 
1B). TB was slightly more prevalent among males than females included in the study (68 % and 213 
32 % respectively (Figure 1C). All 141 sputum samples were smear-positive using one or both 214 
AFB staining methods. Thirty-one specimens were excluded from analysis due to contamination 215 
of the LJ media or because the mycobacteria failed to grow. 216 
 217 
MYCODirect and MYCOResistance LCD-array 218 
Transport of gDNA resulted in loss of DNA integrity in some samples (data not shown). However, 219 
the concentration of extracted DNA ranged from 22.5ng/µl to 657 ng/µl with A260/280 purity of 220 
1.6 to 2 which was considered suitable for the study. IS6110 PCR was positive for all 110 samples 221 
amplified with MYCODirect primers indicating M. tuberculosis. Thirty-nine samples which were 222 
hybridized on MYCODirect microarrays yielded a positive result for M. tuberculosis. Some 223 
variability was seen in intensity of the colourimetric microarray signals due to differences in the 224 
concentration of template DNA used in the PCR.  225 
 226 
Hybridisation of triplex rpoB, inhA and katG PCR products to the MYCOResist LCD-array showed 227 
that 34 (31%) MTBC isolates were sensitive to both RIF and INH (Figure 3). Seventy five (69%) 228 
MTBC isolates contained SNP mutations conferring a range of resistance genotypes (Table 2 and 229 
Figure 4). Monoresistant strains made up 32% of isolates tested, of which 83% were RIF resistant. 230 
The most common mutations found in each resistance gene were rpoB S531L (50% frequency), 231 
inhA C15T (25%), and katG S315T (15%). Other SNPs were found at katG S315N (5%), rpoB 232 
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L533P (5%), rpoB H526Y (4%), rpoB D516V (3%), rpoB S531W (2%) and rpoB H526D (2%). 233 
Of the resistant isolates, 40 (36%) were found to be multidrug-resistant. The most common 234 
MDRTB genotypes were rpoB S531L with inhA C15T (60% of the multidrug-resistant isolates) 235 
and rpoB S531L with katG S315T (20%). A greyscale image showing typical hybridisation 236 
signals for MDRTB (clinical isolate 16) using the MYCOResist LCD-array is shown in Figure 2A. 237 
Figure 2B shows the corresponding colour intensity of the hybridisation signal for each feature 238 
with SNPs identified at rpoB S513L and inhA C15T. 239 
 240 
Comparison of MYCOResist LCD-array and GenoType MTBDRplus for the 241 
detection of resistance to RIF and/or INH 242 
RIF resistance or susceptibility was correctly identified in all DNA extracts provided by SMRL 243 
based on results of MYCOResist LCD-array and the GenoType MTBDRplus analysis. In five of 8 244 
(63%) SMRL samples, mutations identified were concurrent between MYCOResist LCD-array and 245 
GenoType MTBDRplus (Table 1). A mutation conferring resistance to INH was not detected by 246 
the LCD-array in two MDR-TB samples and GenoType MTBDRplus also failed to detect a INH 247 
resistance mutation. Another discrepancy was found in one sample due to the identification of an 248 
incorrect SNP in inhA. To assess the sensitivity and specificity of both methods a larger sample 249 
number would be required but this was not an aim of this study.  250 
 251 
Genotypic compared with phenotypic DST 252 
Where comparison is possible (20%/22 isolates), MYCOResist results showed also good correlation 253 
with phenotypic DST results (Table 2). As a result of time demands of DST and limited resources, 254 
testing analysis of all samples was not undertaken and twenty percent of study samples were 255 
considered adequate for robust comparison with genotypic data. Using the molecular test, a rpoB 256 
mutation was found in 15 clinical isolates which had also been determined to be RIF-resistant by 257 
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phenotypic methods. Similarly, 10 clinical isolates which were found to be INH-resistant using 258 
phenotypic methods gave a positive hybridisation signal for an inhA or katG mutation using the 259 
MYCOResist array. No mutations were found by genotypic analysis in 6 MTBC which were fully 260 
sensitive to both INH and RIF by phenotypic DST. Only one sample (clinical isolate 34) gave a 261 
discrepant result. Relative to phenotypic DST analysis, isolate 34 yielded a false positive result 262 
of INH resistance.  263 
 264 
Discussion 265 
Diagnosis of TB and MDRTB, particularly in developing countries is based on time consuming, 266 
culture-based tests that have been in use for many decades and are a significant impediment to 267 
global TB control. Rapid detection of TB drug resistance is critical to patient care but the 268 
turnaround of culture-based DSTs diminishes their clinical impact. LCD arrays allow more rapid 269 
turnaround times and potentially faster initiation of appropriate treatment which may reduce 270 
spread of TB disease. In Iraq, the emergence of resistance and in particular MDRTB has become 271 
a major public health problem (World Health Organization (WHO), 2012b). Application of the 272 
easy to use molecular method, suitable for use in resource-limited laboratory settings, has 273 
facilitated clinical evaluation of MDRTB of samples from Baghdad (58%) and a broad 274 
geographical distribution of Iraqi provinces (42%). The study has yielded data on prevalence 275 
which reflects benchmark methods and WHO data, and additional data on frequency of resistance 276 
genotypes.   277 
 278 
Our SNP frequency findings are in keeping to those reported around the world. The rpoB S531L 279 
SNP is the most common mutation site associated with RIF resistance, but the frequency of other 280 
rpoB mutations varies depending on geographical location (Kapur et al., 1994; Mani et al., 2003; 281 
Pozzi et al., 1999; Soudani et al., 2007). rpoB mutations at position H526Y and S512T feature at 282 
high frequency in many regions, and this is not seen herein (Cavusoglu et al., 2002; Sajduda, 283 
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Brzostek, Poplawska, Augustynowicz-Kopec, Zwolska, Niemann, Dziadek & Hillemann, 2004). 284 
Although katG codon315 was the only site on this gene interrogated in this study, mutations at 285 
this position have been frequently reported in both INH-resistant, and MDRTB strains (Hillemann 286 
et al., 2005; Mokrousov et al., 2002; van Soolingen et al., 2000; Viader-Salvado et al., 2003). A 287 
number of isolates in this study were found to have a SNP at inhAC15T. This mutation has also 288 
been reported in various geographical locations, but is considered responsible to a lesser extent 289 
for INH resistance (Bakonyte et al., 2003; Jiao et al., 2007; Wu et al., 2006). Frequency 290 
distribution of SNPs identified in our study are corroborated in many European genotypic 291 
MDRTB studies (Hillemann, Weizenegger, Kubica, Richter & Niemann, 2005; Sajduda, 292 
Brzostek, Poplawska, Augustynowicz-Kopec, Zwolska, Niemann, Dziadek & Hillemann, 2004). 293 
MDRTB resistance profiles and prevalence identified herein are similar to other findings in the 294 
WHO Eastern Mediterranean Region. For example, in Saudi Arabia, SNP frequencies and 295 
incidence of MDRTB levels are also similar at 39%, although a different population tested (Nimri 296 
et al., 2011). A recent genotypic study in Jordan found rpoB S531, rpoB516, rpoB526and katG 297 
to be of highest frequency, with incidence of MDRTB at 6% based on newly diagnosed TB cases. 298 
Similar SNP frequency distribution findings were reported in Iran (Khosravi et al., 2012). 299 
According to the WHO, MDRTB is found in 8.1% (Turkey), 9% (Saudi Arabia), 26% (Syria), 300 
29% (Iran), and 48% (Jordan) of Category II TB cases (World Health Organization (WHO), 301 
2012c). Our study shows MDRTB in category II TB cases in Iraq to be amongst the highest 302 
prevalence countries in the region.  303 
 304 
In conclusion, the MYCOResist LCD-array was successfully employed to identify the frequency of 305 
specific rpoB, katG and inhA mutations that confer resistance in Iraqi category II TB cases. The 306 
test is simple, cost effective and rapid. Results showed widespread occurrence of mono-resistant 307 
genotypes and MDRTB. A genotypic study of this nature provides insight into drug resistance 308 
patterns for this region in which prevalence of drug resistant TB is an ongoing problem.  309 
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Figure captions 430 
 431 
Figure 1: Geographical distribution of samples within provinces of Iraq (a) (map of Iraqi 432 
provinces downloaded from http://www.d-maps.com/carte.php?num_car=4295&lang=en; 02 433 
November 2015). (b) shows age distribution of patients included in the study. (c) shows gender 434 
distribution within the study (35 female patients and 75 male patients).  435 
 436 
Figure 2: An example of high-resolution grey-scale image (top right) taken using a 437 
transmission-light film scanning device (Chipron GmbH, Germany) of the MYCOResist array 438 
following hybridization of clinical isolate 16. The top right figure shows the quantified intensity 439 
values.  440 
 441 
Figure 3: Frequency distribution of genotypic antibiotic resistance detected in 110 clinical 442 
isolates from Iraqi category II TB patients studied. 443 
 444 
Figure 4: Frequency distribution of SNPs identified amongst three genes investigated in 110 445 
clinical isolates tested. Highest frequency is identified in rpoB S513L, inhAC15T and katG 446 
S315T. 447 
 448 
449 
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 Table 1: Comparison of MYCOResist LCD-array and GenoType MTBDRplus for detection of 450 
resistance to RIF and/or INH: 451 
 
SMRL Lab No. 
Group B 
Phenotypic DST 
Resistance mutation 
detected by GenoType 
MTBDRplus 
Resistance mutation 
detected by MYCOResist 
LCD-array 
MR216581T (A) RIF-S, INH-R 
katG MUT1 (S315T1) 
AGC→ACC 
katGS315N 
AGC→AAC 
MR171425H (B) RIF-S, INH-R 
katGMUT1 (S315T1) 
AGC→ACC 
inhA MUT1 (C15T) 
katG S315N 
AGC→AAC 
inhA C15T 
MR122781F (C) RIF-R, INH-S 
rpoB MUT3 (S531L) 
TCG→TTG 
rpoB S531L 
TCG→TTG 
MR151475B (D) RIF-R, INH-R 
rpoB MUT3 (S531L) 
TCG→TTG 
katGMUT1 (S315T1) 
AGC→ACC 
rpoB S531L 
TCG→TTG 
No inhA mutation detected 
MR199029V (E) RIF-S, RIF-S None no mutation 
MR135612M (F) RIF-R, INH-R 
rpoBMUT3 (S531L) 
TCG→TTG 
rpoB S531L 
TCG→TTG 
MR164347P (G) RIF-S, INH-R inhA MUT3B (T8A) inhA C15T 
MR188497P (H) RIF-S, INH-R inhA MUT1 (C15T) inhA C15T 
452 
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Table 2: Genotypic and phenotypic drug susceptibility results for 110 tested isolates: 453 
Sample ID Mutation 
detected by 
MYCOResist 
Phenotypic 
Resistance 
INH\RIF 
Sample ID Mutation 
detected by 
MYCOResist 
Phenotypic 
Resistance 
INH\RIF 
1 katGS315T NA 56 rpoB S531L NA 
2 katGS315T, 
rpoB S531L 
NA 57 rpoB S531L NA 
3 No mutation 
detected 
NA 58 No mutation 
detected 
NA 
4 inhA C15T, 
rpoB S531L 
NA 59 rpoB D516V NA 
5 No mutation 
detected 
NA 60 No mutation 
detected 
NA 
6 rpoB S531L S\R 61 rpoB H526Y NA 
7 rpoB H526Y S\R 62 No mutation 
detected 
NA 
8 inhA C15T, 
rpoB S531L 
NA 63 rpoB S531L, 
inhA C15T 
NA 
9 No mutation 
detected 
NA 64 rpoB S531L, 
inhA C15T 
NA 
10 rpoB S531L NA 65 No mutation 
detected 
NA 
11 katGS315T, 
rpoB D516V 
R\R 66 rpoB S531L, 
inhA C15T 
NA 
12 rpoB H526Y, 
katGS315N 
R\R 67 rpoB S531L NA 
13 No mutation 
detected 
S\S 68 rpoB S531L NA 
14 No mutation 
detected 
NA 69 rpoB S531L, 
katGS315N 
NA 
 24 
 454 
15 rpoB S531L NA 70 rpoB S531L NA 
16 rpoB S531L, 
inhA C15T 
NA 71 rpoB S531L NA 
17 rpoB S531L, 
inhA C15T 
NA 72 rpoB L533P, 
katGS315T 
NA 
18 rpoB S531L, 
inhA C15T 
R\R 73 rpoB S531L, 
katGS315T 
NA 
19 rpoB S531L, 
inhA C15T 
R\R 74 rpoB S531L, 
inhA C15T 
NA 
20 No mutation 
detected 
S\S 75 No mutation 
detected 
NA 
21 rpoB S531L S\R 76 rpoB S531W, 
rpoB S531L 
NA 
22 rpoB S531L NA 77 rpoB H526D, 
katGS315N 
NA 
23 rpoB S531L NA 78 katGS315T, 
rpoB S531L 
NA 
24 rpoB L533P, 
inhA C15T 
NA 79 katGS315T NA 
25 rpoB S531L, 
inhA C15T 
NA 80 rpoB S531L, 
inhA C15T 
NA 
26 No mutation 
detected 
NA 81 No mutation 
detected 
NA 
27 No mutation 
detected 
S\S 82 rpoB S531L NA 
28 No mutation 
detected 
NA 83 katGS315T NA 
29 No mutation 
detected 
S\S 84 No mutation 
detected 
NA 
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NA: Not applicable, testing not performed, R= Resistant, S= Sensitive. 455 
30 katGS315T R\S 85 No mutation 
detected 
NA 
31 rpoB S531L, 
inhA C15T 
R\R 86 rpoB S531L, 
inhA C15T 
NA 
32 rpoB S531L, 
inhA C15T 
S\R 87 rpoB S531L, 
katGS315T 
NA 
33 rpoB S531L R\R 88 No mutation 
detected 
NA 
34 rpoBL531L, 
inhA C15T 
S\R 89 No mutation 
detected 
NA 
35 rpoB L533P, 
katGS315T 
NA 90 rpoB S531L, 
katGS315T 
NA 
36 rpoB S531W NA 91 rpoB S531L NA 
37 rpoB S531L, 
inhA C15T 
NA 92 No mutation 
detected 
NA 
38 rpoB L533P, 
inhA C15T 
NA 93 No mutation 
detected 
NA 
39 rpoB S531L, 
inhA C15T 
NA 94 rpoB S531L NA 
40 No mutation 
detected 
NA 95 rpoB S531L NA 
41 No mutation 
detected 
NA 96 No mutation 
detected 
NA 
42 rpoB S531L, 
inhA C15T 
R\R 97 No mutation 
detected 
NA 
43 rpoB H526D, 
katG S315T 
R\R 98 rpoB S531L, 
inhA C15T 
NA 
44 rpoB S531L, 
inhA C15T 
NA 99 rpoB S531L, 
inhA C15T 
NA 
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45 No mutation 
detected 
S\S 100 No mutation 
detected 
NA 
46 No mutation 
detected 
NA 101 No mutation 
detected 
NA 
47 rpoB S531L NA 102 No mutation 
detected 
NA 
48 rpoB S531L, 
katGS315T 
R\R 103 rpoB S531L NA 
49 No mutation 
detected 
S\S 104 rpoB S531L NA 
50 rpoB D516V S\R 105 rpoB S531L NA 
51 rpoB S531L, 
inhA C15T 
NA 106 rpoB 
H526Y,katG 
S315N 
NA 
52 rpoB S531L, 
inhA C15T 
NA 107 rpoB S531L, 
katGS315T 
NA 
53 No mutation 
detected 
NA 108 rpoB S531L, 
katGS315T 
NA 
54 No mutation 
detected 
NA 109 katGS315T, 
inhA C15T 
NA 
55 No mutation 
detected 
NA 110 katGS315T NA 
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